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Aims
The aim of this study was to determine whether patients with metal-on-metal (MoM) 
arthroplasties of the hip have an increased risk of cardiac failure compared with those with 
alternative types of arthroplasties (non-MoM).
Patients and Methods
A linkage study between the National Joint Registry, Hospital Episodes Statistics and records 
of the Office for National Statistics on deaths was undertaken. Patients who underwent 
elective total hip arthroplasty between January 2003 and December 2014 with no past history 
of cardiac failure were included and stratified as having either a MoM (n = 53 529) or a non-
MoM (n = 482 247) arthroplasty. The primary outcome measure was the time to an 
admission to hospital for cardiac failure or death. Analysis was carried out using data from 
all patients and from those matched by propensity score.
Results
The risk of cardiac failure was lower in the MoM cohort compared with the non-MoM cohort 
(adjusted hazard ratio (aHR) 0.901; 95% confidence interval (CI) 0.853 to 0.953). The risk of 
cardiac failure was similar following matching (aHR 0.909; 95% CI 0.838 to 0.987) and the 
findings were consistent in subgroup analysis.
Conclusion
The risk of cardiac failure following total hip arthroplasty was not increased in those in 
whom MoM implants were used, compared with those in whom other types of prostheses 
were used, in the first seven years after surgery.
Cite this article: Bone Joint J 2018;100-B:20–7.
Metal-on-metal (MoM) prostheses of the hip
have been widely used,1 but are now known to
have unacceptably high rates of failure.2-4 This
has triggered regulatory alerts, device recalls
and mandatory surveillance programs. The
failure of these devices has led to many patients
subsequently undergoing early revision.5-8
Corrosion and wear of MoM implants, which
are composed of cobalt-chromium alloy, can
result in the release of particulate debris and
metal ions into the circulation. Alongside
localized effects, MoM prostheses have been
associated with systemic complications such as
cardiotoxicity and mortality.9-14 Concerns
have been recently raised about cobalt cardio-
myopathy, particularly following the report of
a three-fold increased risk in hospital admis-
sions due to cardiac failure in a subgroup of
men with MoM prostheses.15,16 The findings
have, however, been inconsistent.13,17,18 The
symptoms and signs of cardiac failure are com-
mon in patients undergoing total hip arthro-
plasty (THA) and any association between the
type of prosthesis and cardiac failure present-
ing at a later date, and usually to a different cli-
nician, could easily be overlooked.19
Record-linkage studies have been used to
investigate the relationship between death due
to cancer in patients who have undergone
MoM THA, concluding that there is no
increased risk.20-22 In this study, we tested the
hypothesis that MoM THA was associated
with increased risk of cardiac failure compared
with other types of prostheses.
Patients and Methods
This was a retrospective cohort study using
linked national data sets. The United Kingdom
National Joint Registry (NJR), which is the
largest arthroplasty registry in the world,23
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was the primary source of data for this study. The submis-
sion of data to the registry has been mandatory for
National Health Service (NHS) hospitals in England, Wales
and Northern Ireland since 1 April 2011, with > 95% of
primary procedures captured in 2015 and now with infor-
mation from more than two million arthroplasties.23
Each record describes the demographics of the patient
including age, gender, American Society of Anesthesiolo-
gists (ASA) grade,24 body mass index (BMI), the type of
prosthesis including the bearing surface, size of the compo-
nents and brand and surgical details. Corresponding data
are generated routinely for NHS Hospital Episodes Statis-
tics (HES),25 which specify the reasons for admission, pro-
cedures performed and length of stay. The Office for
National Statistics (ONS)26 records death certification data
on all deaths registered in England and Wales including the
date and cause(s) of death.
Individual patient-level record linkage was carried out by
NHS Digital (NHS, Leeds, United Kingdom), using the
NHS number, date of birth, gender and postcode. Only
patients consenting to inclusion in the NJR registry and to
the use of their data for research purposes were included.
Pseudo-anonymous data from the NJR were provided to
the investigators for analysis. The study was undertaken in
accordance with the Strengthening the Reporting of Obser-
vational studies in Epidemiology (STROBE) checklist.27
The inclusion criteria involved those who underwent
elective, primary THA between 1 January 2003 and 31
December 2014 who had linked HES records. This pro-
vided a minimum period of six preoperative years in which
to establish a record of cardiac failure at the time of THA
and a minimum postoperative follow-up of six months.
Patients with cardiac failure prior to or in the six months
following THA, which would most likely have been attrib-
utable to pre-existing disease, were excluded from the over-
all analysis but included in sensitivity analyses. A step-wise
process was used to remove records of insufficient quality
and cases with duplicate or conflicting data. The exposure
of interest was defined as the type of arthroplasty. The
MoM cohort included patients with metal acetabular and
femoral components which articulated directly; both resur-
facing and stemmed arthroplasties were included. Expo-
sure dated from the first primary arthroplasty. Patients
with both a MoM and a non-MoM arthroplasty were
excluded.
The primary outcome measure was the time to an episode
of cardiac failure following arthroplasty. The secondary out-
come measure was all causes of mortality. The time at risk
for the outcome was measured from the day of the arthro-
plasty until the first hospital admission with cardiac failure,
death or the end of the study period (March 2015). Cardiac
failure was defined by the appropriate diagnostic codes fol-
lowing discharge from hospital or on a death certificate (see
supplementary material). The demographics of the patients
and details of the operation were extracted from NJR and
comorbidities were extracted from HES data.
The study protocol was approved by the Research Sub-
committee of the NJR and the Data Access Advisory Group
of NHS Digital.
Statistical analysis. Cox proportional hazards models were
used to estimate the hazard ratio (HR) for primary and sec-
ondary outcomes by group and were adjusted for potential
confounding factors including age at the time of the opera-
tion, gender, a history of type 2 diabetes, hypertension, cor-
onary heart disease and other indicators of comorbidity
and frailty (Charlson comorbidity index,28 ASA grade and
the number and length of hospital admissions in the five
years prior to arthroplasty).
In order to control for the indications available in the data
set, propensity-matched analyses (adjusted and unadjusted)
were performed using one-to-one matching of patients
undergoing MoM arthroplasty with those undergoing a non-
MoM arthroplasty. The cohort was stratified by gender
before propensity matching and matched by age, history of
diabetes, heart disease and hypertension, Charlson index and
ASA class. A caliper of 0.2 was used for the propensity score.
Further comparisons were performed for subgroups,
including those at the highest risk of cardiac failure and those
at the highest risk of implant failure,29 including those with
an Articular Surface Replacement (ASR) XL Acetabular Sys-
tem (DePuy Orthopaedics, Warsaw, Indiana). BMI was
available for approximately half of the patients (n = 278 757)
and was included as a further covariate for this subset. Data
processing was performed using Microsoft SQL Server 2012
(Redmond, Washington), and statistical analyses with SPSS
Statistics version 22.0 (IBM, Armonk, New York). The pro-
portional hazards assumption was tested using the correla-
tion between survival and partial residuals.
Results
A total of 581 954 patients with a THA recorded in the
NJR could be linked to HES and ONS data. Following data
cleaning and the exclusion of emergency admissions, 550
589 (94.6%) THAs remained. Of these, 535 776 (97.3%)
had no history of cardiac failure either before their arthro-
plasty or within the subsequent six months. This cohort
was used in the main analysis (Fig. 1). A total of 53 529
patients (10.0%) had a MoM hip arthroplasty and were
matched in the propensity analysis. Notably, the patients
were younger (mean age: 58.6 years, SD 11.1) versus 69.2
years, SD 11.0). More were male (61.1% versus 38.1%)
with fewer comorbidities, as measured by the prevalence of
diabetes, coronary heart disease and hypertension, Charl-
son index and ASA grade (Table I). By design, propensity
matching reduced these differences (Table I).
There were 1431 incidents of cardiac failure in the MoM
cohort and 21 245 in the non-MoM cohort. The crude
event rates were 3.8 and 9.7 per 1 000 person years’ expo-
sure, respectively, with a crude relative rate of 0.389 (95%
confidence interval (CI) 0.368 to 0.410, Table II). Follow-
ing adjustment, the adjusted hazard ratio (aHR) for the
MoM cohort relative to the non-MoM cohort was 0.901
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(95% CI 0.853 to 0.953, Table III). In unadjusted analysis,
the relative rate of all-cause mortality was 0.389 (95% CI
0.376 to 0.402). Following adjustment, the HR for all-
cause mortality was 0.892 (95% CI 0.862 to 0.924).
In subgroup analyses, the aHR was below unity or did not
achieve significance for all groups (Fig. 2. In the age-specific
subgroup analysis, there was a trend towards an increasing
rate of cardiac failure with increasing age, ranging from
0.600 (0.353 to 1.019) in the youngest cohort (≤ 44 years) to
1.15 (0.908 to 1.370) in the oldest (≥ 85 years).
In the propensity-matched analysis, there were 1431
incidents of cardiac failure in the MoM cohort and 1004 in
the non-MoM cohort. Due to the longer follow-up, the
crude event rates were lower in the MoM cohort (3.8 events
per 1000 person years versus 4.1 events per 1000 person
years), with an unadjusted relative rate of 0.917 (95% CI
0.846 to 0.994, Table II). In adjusted analyses, the aHR was
0.909 (95% CI 0.838 to 0.987, Table III). For all-cause
mortality, the aHR was 0.877 (95% CI 0.835 to 0.922,
Table III). The subgroup analysis of the propensity-
matched cohorts is illustrated in Figure 3. No subgroup had
a significantly increased aHR.
A total of 557 patients in the MoM cohort and 14 256 in
the non-MoM cohort had a previous history of cardiac fail-
ure. The respective event rates for the first subsequent
admission with cardiac failure were 136.6 and 195.3 per
1000 person years (Table IV). After adjustment, the aHRs
for cardiac failure and all-cause mortality were 0.997 (95%
CI 0.885 to 1.122; p = 0.952) and 0.983 (95% CI 0.854 to
1.132; p = 0.814), respectively. In the analysis that included
BMI as a covariate, the aHRs for cardiac failure and all-
cause mortality were 0.920 (95% CI 0.831 to 1.019) and
0.879 (95% CI 0.850 to 0.909), respectively.
Additional analyses were performed on the MoM cohort
by the type of device including the type of head, the brand
of the acetabular component and the size of the compo-
nents. For patients receiving a modular head, the aHR
approximated unity (aHR = 1.013; 95% CI 0.953 to
1.078). Of these patients, the aHR for those receiving an
ASR XL prosthesis was 0.970 (95% CI 0.776 to 1.213).
For those having a resurfacing, the aHR was significantly
lower (0.656; 95% CI 0.587 to 0.732, Table V). No brand
of acetabular component or size of femoral head had an
increased aHR for cardiac failure (supplementary fig a).
Discussion
In this study involving more than half a million patients
with arthroplasties of the hip, there was no association
between a MoM arthroplasty and an increased incidence of
cardiac failure in the first seven years after surgery.
Table I. Baseline characteristics of patients with metal-on-metal and non-metal-on-metal arthroplasties: all patients and those matched by propen-
sity score
All patients Propensity-matched patients
MoM Non-MoM p-value MoM Non-MoM p-value
Number of patients 53 529 482 247 N/A 53 529 53 529
Mean follow-up, yrs (SD) 7.2 (2.3) 4.6 (3.0) < 0.001* 7.2 (2.3) 4.6 (3.1) < 0.001*
Mean age, yrs (SD) 58.6 (11.1) 69.2 (11.0) < 0.001* 58.6 (11.1) 58.6 (11.8) 0.004*
Gender, n (%) < 0.001† 1†
Male 32 700 (61.1) 183 867 (38.1) 32 700 (61.1) 32 700 (61.1)
Female 20 829 (38.9) 298 380 (61.9) 20 829 (38.9) 20 829 (38.9)
Mean body mass index, kg/m2 (SD) 28.4 (5.2) 28.5 (5.3) 0.170* 28.4 (5.2) 28.7 (5.2) < 0.001*
Prior type 2 diabetes, n (%) 2034 (3.8) 38 575 (8) < 0.001† 2034 (3.8) 1922 (3.6) 0.070†
Prior hypertension, n (%) 11 171 (20.9) 197 830 (41.0) < 0.001† 11 171 (20.9) 10 436 (19.5) < 0.001†
Prior coronary heart disease, n (%) 2966 (5.5) 53 239 (11) < 0.001† 2966 (5.5) 2710 (5.1) 0.001†
Mean Charlson Index (SD) 0.2 (0.7) 0.5 (1) < 0.001* 0.2 (0.7) 0.2 (0.6) < 0.001*
Prior hospitalisations
Mean total admissions (SD) 1.4 (3.2) 2.1 (7.6) < 0.001* 1.4 (3.2) 1.4 (2.6) < 0.001*
Mean hospitalized days (SD) 4.4 (17.6) 6.5 (20.3) < 0.001* 4.4 (17.6) 4.3 (18.0) < 0.001*
ASA, n (%) < 0.001† < 0.001†
P1 - Fit and healthy 20 892 (39) 79 107 (16.4) 20 892 (39.0) 19 998 (37.4)
P2 - Mild disease not incapacitating 29 158 (54.5) 335 415 (69.6) 29 158 (54.5) 30 868 (57.7)
P3 - Incapacitating systemic disease 3362 (6.3) 65 896 (13.7) 3362 (6.3) 2621 (4.9)
P4 - Life threatening disease 100 (0.2) 1742 (0.4) 100 (0.2) 38 (0.1)
P5 - Expected to die within 24 hrs 17 (0) 87 (0) 17 (0) 4 (0)
Ethnicity, n (%) < 0.001† < 0.001†
Asian 213 (0.4) 1531 (0.3) 213 (0.4) 330 (0.6)
Black 399 (0.7) 2229 (0.5) 399 (0.7) 461 (0.9)
Chinese 10 (0) 158 (0) 10 (0) 20 (0)
Mixed 98 (0.2) 638 (0.1) 98 (0.2) 137 (0.3)
Not recorded 8686 (16.2) 63 900 (13.3) 8686 (16.2) 7617 (14.2)
Other 201 (0.4) 1597 (0.3) 201 (0.4) 258 (0.5)
White 40 391 (75.5) 398 401 (82.6) 40 391 (75.5) 42 278 (79)
*Student’s t-test
†chi-squared test
MoM, metal-on-metal; SD, standard deviation; ASA, American Society of Anesthesiologists
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In contrast to the recent report of increased rates of
admission with cardiac failure in subgroups of patients
with MoM arthroplasties,15 the risk of cardiac failure in
these patients appeared to be lower than those with other
types of bearing surfaces. These findings persisted after
extensive adjustment for confounding factors, after match-
ing by propensity score and even among patients at the
highest risk of either cardiac failure or implant failure.
Patients with pre-existing cardiac failure had, as expected,
significantly higher rates of admission with cardiac failure
and death due to cardiac failure. However, this was not
influenced by exposure to MoM arthroplasty. In common
with other studies,20,21 we found no increase in all-causes of
mortality with MoM arthroplasty.
It is however, likely that there are residual confounding
factors for which we have failed to account. Our finding
that the lower rate for all causes of mortality from MoM
arthroplasties was markedly attenuated by multivariate
adjustment and matching by propensity score, indicates
that this is likely to be due to lower morbidity. These results
are in line with previously published studies assessing the
risk of cancer and mortality with these patients, in which
similarly lower HRs were reported, particularly in patients
with a MoM resurfacing.18,21,30 Resurfacing is a bone-con-
serving option, sought by patients aiming to return to high
levels of function. Aspects of better health which are not
captured in these data such as exercise and not smoking or
socioeconomic status may explain these findings.
The use of modular MoM arthroplasties was more var-
ied, with some patients receiving them because they were
deemed to be at high a risk of dislocation. This includes
patients with poor musculature, neurological disorders,
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Fig. 1
Flowchart showing data linkage, data cleaning and selection of the cohorts. NJR, National Joint Registry;
NHS, National Health Service; HES, hospital episode statistics, MoM, metal-on-metal
24 S. A. SABAH, J. C. MOON, S. JENKINS-JONES, ET AL
Follow us @BoneJointJ THE BONE & JOINT JOURNAL
variations in anatomy and other factors that may be asso-
ciated with a poorer outcome. These patients therefore
have more in common with those undergoing non-MoM
arthroplasty than those undergoing a resurfacing This is
reflected in our findings, in which the HR for cardiac fail-
ure in patients undergoing a modular MoM arthroplasty
was close to unity, and thus higher than in those undergoing
a resurfacing.
Table II. Incidents, the rate of events and the crude relative risk of heart failure and all-cause mortality for patients with metal-on-metal and
non-metal-on-metal arthroplasties: all patients and those matched by propensity score
MoM Non-MoM
Crude relative risk 
(95% CI)
Patients Events Rate* Patients Events Rate*
All patients
Cardiac failure 53 529 1431 3.8 482 247 21 245 9.7 0.389 (0.368 to 0.410)
Death 53 529 3728 9.7 482 247 55 875 24.9 0.389 (0.376 to 0.402)
Propensity-matched patients
Cardiac failure 53 529 1431 3.8 53 529 1004 4.1 0.917 (0.846 to 0.994)
Death 53 529 3728 9.7 53 529 2776 11.2 0.864 (0.823 to 0.908)
*rate per 1000 person years’ exposure
MoM, metal-on-metal; CI, confidence interval
Table III. Adjusted hazard ratio of cardiac failure and all-cause mortality for patients with metal-on-metal
and non-metal-on-metal arthroplasties: all patients and those matched by propensity score
Adjusted hazard ratio (95% CI) p-value*
All patients
Cardiac failure 0.901 (0.853 to 0.953) < 0.001
Death 0.892 (0.862 to 0.924) < 0.001
Propensity-matched patients
Cardiac failure 0.909 (0.838 to 0.987) 0.023
Death 0.877 (0.835 to 0.922) < 0.001
*Cox PH model 
CI, confidence interval
Hazard ratio (95% CI)
0.5 1.0 2.0
Sub-group aHR
0.881 (0.819 to 0.947)
0.951 (0.846 to 1.069)
0.900 (0.845 to 0.958)
0.896 (0.838 to 0.958)
0.953 (0.764 to 1.188)
1.005 (0.852 to 1.186)
0.917 (0.803 to 1.047)
0.922 (0.867 to 0.98)
0.923 (0.861 to 0.989)
0.925 (0.843 to 1.014)
9694/216 567
12 982/319 209
19 760/495 167
2916/409 609
17 067/479 571
5609/56 205
1742/62 681
2852/112 693
3195/103 383
2231/99 999
20 445/435 777
13 486/383 187
9190/152 589
72/18 153
321/44 966
1810/117 636
6546/187 275
10 657/140 533
3270/27 2101.115 (0.908 to 1.370)
1.000 (0.901 to 1.110)
0.941 (0.856 to 1.035)
0.79 (0.701 to 0.890)
0.822 (0.646 to 1.045)
0.600 (0.353 to 1.019)
0.899 (0.824 to 0.981)
0.853 (0.720 to 1.010)
0.915 (0.863 to 0.971)
95% CI Patients
Gender Male
Female
Diabetes Diabetes
Non-diabetes
CHD CHD
Non-CHD
< 25
25 to 29.9
30+
1
2 to 5
0
1+
12 to 44
45 to 54
55 to 64
65 to 74
75 to 84
85+
BMI
ASA
Charlson
Age
Fig. 2
Adjusted hazard ratio (aHR) of cardiac failure for patients with metal-on-metal (MoM) and non-MoM arthroplasties: all patients by subgroup. CI,
confidence interval; CHD, coronary heart disease; BMI, body mass index; ASA, American Society of Anesthesiologists grade.
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MoM arthroplasties vary both in design and manufac-
turing process, and have different rates of failure and circu-
lating levels of metal ions.29,31,32 Subgroup analysis by
manufacturer found no differences between devices associ-
ated with high rates of implant failure such as stemmed
implants, those with a large femoral head and brands
including the ASR XL and other MoM implants. The ASR
XL (DePuy) is a type of large-diameter, stemmed arthro-
plasty with a high rate of implant failure.33 It was subject to
a worldwide device recall and was recently identified as
being associated with an increased risk of cardiac failure in
elderly men.15
Cobalt cardiomyopathy was first described in 1967 in
patients with excess dietary cobalt, ‘Quebec beer-drinkers’
cardiomyopathy’.33 More recently, case reports and small
series have reported cardiomyopathy related to failure of
MoM implants.7,35-39 However, there were < 30 cases in
total and these patients had extreme levels of circulating
metal ions. Prentice et al40 performed a cross-sectional
observational study of systemic complications and found a
5% lower ejection fraction in 35 patients with MoM resur-
facing implants compared with patients with conventional
arthroplasties. Subsequent multimodality work41 using
both echocardiography and MRI, the benchmark measure
of cardiac function, failed to replicate these findings despite
including patients with high levels of metal ions in the
blood (mean cobalt 30 ppb (range 8 to 118). Using epide-
miological approaches, one study found lower standard-
ized mortality ratios for cardiovascular death in a large
cohort of patients with a MoM arthroplasty compared with
those with a non-MoM arthroplasty.22 Cardiac failure was
not specifically studied. A recent report from Australia
Hazard ratio (95% CI) Sub-group aHR
0.908 (0.818 to 1.008)
0.950 (0.790 to 1.142)
0.898 (0.820 to 0.985)
0.916 (0.829 to 1.012)
0.843 (0.613 to 1.158)
0.846 (0.675 to 1.061)
0.894 (0.746 to 1.072)
0.912 (0.832 to 1.00)
0.914 (0.827  to 1.010)
0.884 (0. 765 to 1.022)
1504/65400
931/41 658
2189/103 102
246/3956
1934/101 382
501/5676
160/9844
278/20 189
322/18 079
493/40 890
1942/66 168
1623/89 499
812/17 559
45/11 383
179/24 972
570/38 847
822/23 010
657/7768
162/10781.010 (0. 733 to 1.391)
1.011 (0.864 to 1.183)
0.930 (0.808 to 1.071)
0.817 (0.687  to 0.973)
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Fig. 3
Adjusted hazard ratio of cardiac failure for patients with metal-on-metal (MoM) and non-MoM arthroplasties: propensity-matched
patients by subgroup. CI, confidence interval; aHR, adjusted hazard ratio; CHD, coronary heart disease; BMI, body mass index; ASA,
American Society of Anesthesiologists grade.
Table IV. Events, the rate of events and adjusted hazard ratio of cardiac failure and all-cause mortality for patients with a history of cardiac failure
and metal-on-metal and non-metal-on-metal arthroplasties
MoM Non-MoM Adjusted hazard ratio (95% CI) p-value†
Patients Events Rate* Patients Events Rate*
Cardiac failure, n 557 293 136.6 14 256 6747 195.3 0.977 (0.885 to 1.122) 0.952
Death, n 557 208 64.6 14 256 4933 96.0 0.983 (0.854 to 1.132) 0.814
*rate per 1000 person years’ exposure
†Cox PH model
MoM, metal-on-metal; CI, confidence interval
26 S. A. SABAH, J. C. MOON, S. JENKINS-JONES, ET AL
Follow us @BoneJointJ THE BONE & JOINT JOURNAL
noted a three-fold increase in the risk of admissions to hos-
pital because of cardiac failure in 63 men with an ASR XL
THA with a mean age of 82 years, compared with 1502
men with a metal-on-plastic THA.14 These patients were
significantly different from our patients, both in age and
risk of cardiac failure. All patients in their study had a high
rate of cardiac failure; the incidence of cardiac failure in the
control group was 18% at a mean of 7.2 years, and the
effect was confined to men. In our study, there was no
increased risk of cardiac failure in older patients with an
ASR XL THA (supplementary table ii). The numbers were
small (n = 786), with wide CIs.
This study is the largest epidemiological study of sys-
temic effects (cardiac failure) after MoM arthroplasty.
Given the nature of the sources of the data, case recruit-
ment should be comprehensive and the findings can there-
fore be generally followed. The statistical power of the
dataset enabled extensive subgroup analysis to address spe-
cific concerns such as the differences between gender and
brands.15 We accept that before 2005, the data in the NJR
include less than 80% of the arthroplasties undertaken in
the United Kingdom and some MoM arthroplasties may
have been omitted from the analysis.42
Limitations include those of the HES data, where coding is
not performed by clinicians and the coding of cardiac failure
is imperfect, although this should introduce only analytical
noise, rather than bias. Cardiac failure is mainly captured
when severe, as in admission to hospital or death, missing
cardiac failure diagnosed and managed in a primary care set-
ting. Follow-up was up to seven years only. However, a sys-
tematic review suggested that recognized cases occur within
a median of 19 months (up to six years) postoperatively.7 We
did not include analysis of the levels of metal ions in the
blood. Any association of cardiac failure and high levels of
metal ions could have been missed, but given the mandated
surveillance of these levels and the association of metal ions
with local symptoms, most of these patients would have had
revision surgery. Retrospective analysis of registry data can
rarely be definitive about causality.13,17 There are, however,
no prospective observational or sufficiently powered rand-
omized controlled trials, nor are there likely to be in the
future. There are only two previous studies, both negative
and unpublished,33,42 and no association was reported in a
single, small meta-analysis.13
In conclusion, we found a lower incidence of cardiac failure
and mortality in patients with MoM arthroplasties com-
pared with other types of arthroplasty of the hip in the first
seven years after surgery. While there may be confounding
factors by indication, these results should provide reassur-
ance to clinicians and patients alike, regarding the cardiac
sequelae associated with these devices. We recommend epi-
demiological analysis at five-yearly intervals to investigate
for any latent effects.
Take home message:
Patients with metal-on-metal hip prostheses (of any type) are
not at significantly increased risk of severe heart failure in the
first 7 years after elective surgery.
Supplementary material
Further information including tables and figures are
available alongside the online version of this article at
www.bjj.boneandjoint.org.uk
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